|
|||
2017-02-23 16:30:00 CET 2017-02-23 16:30:00 CET Biohit Oyj - Managers' transactionsCORRECTION: Biohit Oyj - Managers' TransactionsBiohit Oyj - Managers' Transactions, February 23, 2017 at 5:30 pm local time (EET) CORRECTION TO BIOHIT OYJ – MANAGER’S TRANSACTIONS IN FEBRUARY 23, 2017 AT 3:50 PM LOCAL TIME (EET) Transaction details should read as follows: Transaction Details (1): Volume: 13933 Unit price: 3,40920 EUR (2): Volume: 2776 Unit price: 3,70400 EUR (3): Volume: 15299 Unit price: 3,51260 EUR (4): Volume: 3962 Unit price: 3,51260 EUR Aggregated transactions (4): Volume: 35970 Volume weighted average price: 3.48732 EUR The release including the corrected information is found in its entirety below. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Korpela, Semi Position: Chief Executive Officer Issuer: Biohit Oyj LEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATION Reference number: 74370089ATTSNBXJVT29_20170223163749_6 ____________________________________________ Transaction date: 2017-02-20 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT ISIN: FI4000219324 Nature of the transaction: EXERCISE (RIGHTS, PUT AND CALL OPTIONS) (X) Linked to stock option programme Transaction Details (1): Volume: 13933 Unit price: 3,40920 EUR (2): Volume: 2776 Unit price: 3,70400 EUR (3): Volume: 15299 Unit price: 3,51260 EUR (4): Volume: 3962 Unit price: 3,51260 EUR Aggregated transactions (4): Volume: 35970 Volume weighted average price: 3.48732 EUR Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com |
|||
|